glp 1 hims reviews & Hers Super Bowl ad promotes compounded GLP-1 drugs, which aren't FDA-approved Hims & Hers vs. Novo

Pfizer halted development of its oral GLP-1 danuglipron in 2025 after a trial participant developed liver injury, reflecting safety concerns that require ongoing monitoring with real-world data

The motivation behind this journal club conversation [2:45] Overview of todays conversation : This is something Peter and Andrew have been wanting to do for a while and its something they do all the time Peruse the literature and find papers they are excited about This episode will focus on talking about papers we find exciting in real time, for the first time, in podcast format The goal is to give people some sense of why theyre so excited about these papers We feel people should know about these findings Its also an opportunity for people to learn how to dissect information and think about the papers they hear about in the news To start thinking like scientists and clinicians To get a better sense of what it looks like to pick though a paper: the good, the bad, the ugly Papers might be downloaded from PubMed Peter used to run a journal club inside his practice Once a month a person would pick a paper and we would go through it in a formal journal club presentation Weve gotten away from it for the last year just because weve been a little stretched thin Peter thinks its something we need to resume because its a great way to learn and its a skill People probably ask Andrew all the time, What are the dos and donts of interpreting scientific papers

First time doing an IV and my experience was amazing

This will give us an eye toward broader outcomes and implications of these drugs, Blaha said

David Geier is an orthopedic surgeon and sports medicine specialist in Charleston, South Carolina and Charlotte, North Carolina